Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting key parameters in pharmaceutical formulations by principal component analysis.

N R Bohidar, F A Restaino, J B Schwartz

    Journal of Pharmaceutical Sciences
    |June 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Patterns of chronic co-morbid medical conditions in older residents of U.S. nursing homes: differences between the sexes and across the agespan.

    The journal of nutrition, health & aging·2014
    Same author

    A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations.

    The Journal of clinical endocrinology and metabolism·2014
    Same author

    Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".

    Clinical pharmacology and therapeutics·2013
    Same author

    Variability in free 25(OH) vitamin D levels in clinical populations.

    The Journal of steroid biochemistry and molecular biology·2013
    Same author

    Association of CYP2C9*2 with bosentan-induced liver injury.

    Clinical pharmacology and therapeutics·2013
    Same author

    Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

    Clinical and experimental immunology·2012

    Principal component analysis (PCA) effectively simplifies pharmaceutical formulation selection by identifying key tablet properties like dissolution. This method reduces the number of critical measurements needed, saving time and resources.

    Area of Science:

    • Pharmaceutical Sciences
    • Data Analysis
    • Formulation Development

    Background:

    • Selecting optimal pharmaceutical formulations involves evaluating multiple response variables.
    • Traditional methods can be resource-intensive, requiring extensive measurement of various tablet properties.

    Purpose of the Study:

    • To present the role of principal component analysis (PCA) in pharmaceutical formulation selection.
    • To detail the objective and procedure of applying PCA to tablet properties.

    Main Methods:

    • Application of principal component analysis (PCA).
    • Analysis of 10 response variables representing tablet properties.

    Main Results:

    • The first principal component (dissolution) explained 95.4% of the information.

    Related Experiment Videos

  • Components one and two (dissolution and disintegration) explained 99.3% of the information.
  • Eight of 10 response parameters contributed negligible additional information.

    • Conclusions:

    • PCA significantly reduces the dimensionality of formulation data.
    • This approach offers substantial economies in cost and time for response measurement.
    • PCA aids in understanding the underlying mechanisms of pharmaceutical systems.